

Treatment resistant schizophrenia (TRS)
is the most disabling of all psychiatric illnesses,
affecting about 1/3 of patients



World Congress of Psychiatric Genetics - Satellite symposium

CRESTAR – development of pharmacogenomic biomarkers for schizophrenia

Saturday, October 17th 2015, 6:00pm - 7:30pm
Ontario Room, Fairmont Royal York Hotel
100 Front St W, Toronto, ON M5J 1E3, Canada
contact: Dan.Rujescu@uk-halle.de

Refreshments, wine and cheese will be served
no registration fee



Chairs: David A. Collier, UK
Dan Rujescu, Germany

Speaker: 6:00 p.m. David A. Collier, overview

6:05 p.m. Dan Rujescu, clinical diagnosis of agranulocytosis

6:10 p.m. Pat Sullivan, USA

Genomic study of clozapine-induced agranulocytosis implicates HLA-B

6:30 p.m. Dan Rujescu, Germany

Genomics of agranulocytosis

6:50 p.m. James Walters, UK

GWAS of 11,000 clozapine cases

7:10 p.m. Daniel Müller, Canada

Pharmacogenetics of clozapine treatment response and common side-effects:
Update and implications for the clinician.

Discussants: Danai Dima, Ina Giegling, Marcella Rietschel